Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 9.6% from the September 15th total of 35,400 shares. Based on an average trading volume of 39,300 shares, the short-interest ratio is currently 1.0 days. Currently, 0.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Stock Up 0.6 %

DARE traded up $0.02 during trading on Thursday, reaching $3.60. The company’s stock had a trading volume of 21,076 shares, compared to its average volume of 45,827. The company has a market cap of $30.32 million, a price-to-earnings ratio of -0.93 and a beta of 1.39. The firm has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $4.06. Daré Bioscience has a 1 year low of $3.05 and a 1 year high of $7.56.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. As a group, equities analysts forecast that Daré Bioscience will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.